about
siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cellsTargeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1.Activating HER3 mutations in breast cancer.
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
HER3 as a Therapeutic Target in Cancer.
@en
type
label
HER3 as a Therapeutic Target in Cancer.
@en
prefLabel
HER3 as a Therapeutic Target in Cancer.
@en
P2093
P2860
P1433
P1476
HER3 as a Therapeutic Target in Cancer.
@en
P2093
Aaron E Sosa
Alberto Verlicchi
Chiara Lazzari
Niki Karachaliou
P2860
P2888
P356
10.1007/S40259-016-0205-2
P577
2016-12-20T00:00:00Z